PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

roflumilast

Verify with FDA → · CMS NADAC pricing →

Brand names: Daliresp

PDE4 Inhibitor Rx

Roflumilast (Daliresp) helps to reduce flare-ups in people with severe COPD. It is for people who also have chronic bronchitis and a history of COPD flare-ups.

Drug Pricing (NADAC)

Brand Price

$14.11/unit

Generic Price

$2.34/unit

Generic Savings

83%

Generic Available

Yes (8 manufacturers)

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

What it does

Roflumilast is used to lower your chances of COPD flare-ups.

Common side effects

Diarrhea, Weight loss, Nausea

Key warnings

Roflumilast is not for sudden breathing problems.

How It Works

Roflumilast blocks an enzyme called phosphodiesterase 4 (PDE4). By blocking PDE4, it reduces lung inflammation. This can help prevent COPD flare-ups.

How to Take It

The usual dose is one 500 mcg tablet daily. You can take it with or without food. You might start with a 250 mcg tablet for the first 4 weeks. Then, increase to the 500 mcg dose.

Pregnancy & Breastfeeding

It is not known if roflumilast is safe during pregnancy. Do not breastfeed while taking roflumilast.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose.

Storage

Store roflumilast tablets at room temperature (68°F to 77°F).

Side Effects (from patient reports)

Based on 5,435 FDA adverse event reports.

Difficulty breathing
1,011
Death
729
Chronic lung disease
631
Diarrhea
567
Nausea
465
Pneumonia
450
Weight loss
436
Headache
404
Using the medicine for something it's not approved for
393
The medicine is not working
349

FDA Adverse Event Report Analysis

Detailed analysis of 6,450 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2010–2025.

Total Reports

6,450

Death-Related Reports

943

Hospitalization Reports

1,974

Top Indication

Chronic Obstructive Pulmonary Disease

Gender Distribution

Female 3,084 (54%)
Male 2,626 (46%)

Age Distribution

0–17 37
18–44 134
45–64 1,084
65–74 1,229
75+ 874

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 DYSPNOEA 1,011
2 DEATH 730
3 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 631
4 DIARRHOEA 567
5 NAUSEA 465
6 PNEUMONIA 450
7 WEIGHT DECREASED 436
8 HEADACHE 404
9 OFF LABEL USE 393
10 DRUG INEFFECTIVE 349
11 COUGH 346
12 INSOMNIA 313
13 DIZZINESS 300
14 ASTHMA 284
15 DECREASED APPETITE 282

Reactions in Death Reports

DEATH 729
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 85
PNEUMONIA 46
DYSPNOEA 35
WEIGHT DECREASED 25
ASTHENIA 21
RESPIRATORY FAILURE 20
MALAISE 18
DIARRHOEA 17
FALL 17

Reactions in Hospitalization Reports

DYSPNOEA 520
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 402
PNEUMONIA 346
ASTHMA 170
DIARRHOEA 168
COUGH 164
WEIGHT DECREASED 162
WHEEZING 123
OFF LABEL USE 117
NAUSEA 114

Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Roflumilast is not for sudden breathing problems. It may cause mental health problems, including suicidal thoughts. Tell your doctor if you have mood changes or weight loss.

Known Drug Interactions

rifampicin, phenobarbital, carbamazepine, and phenytoin) with roflumilast tablets is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ].

Mechanism: Carbamazepine causes your body to break down roflumilast much faster than usual. This reduces the amount of medicine in your system and makes it less effective.

What to do: Using these two medications together is not recommended. Your doctor may need to adjust your treatment plan.

moderate phenytoin

rifampicin, phenobarbital, carbamazepine, and phenytoin) with roflumilast tablets is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ].

Mechanism: Phenytoin speeds up the process of clearing roflumilast from your body. This can prevent the medication from reaching levels high enough to work properly.

What to do: This combination is not recommended. Consult your healthcare provider to see if a different medication is right for you.

rifampicin, phenobarbital, carbamazepine, and phenytoin) with roflumilast tablets is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ].

Mechanism: Phenobarbital triggers your body to get rid of roflumilast more quickly. This means the drug will not stay in your body long enough to help your condition.

What to do: Avoid taking these two drugs at the same time. Your doctor should evaluate other options for your care.

7.3 Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of roflumilast tablets (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects.

Mechanism: Taking these together can raise the amount of roflumilast in your body. This happens because the birth control affects how the body processes the medicine.

What to do: Watch for increased side effects if you take these together. Your doctor may need to monitor your health more closely.

Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. 7.2 Drugs that Inhibit Cytochrome P450 (CYP) Enzymes The co-administration of roflumilast tablets (500 mcg) with CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) may increase roflumilast systemic exposure and may result in increased adverse reactions.

Mechanism: Ketoconazole blocks the enzymes that normally break down roflumilast. This causes the medicine to build up in your body and increases the risk of side effects.

What to do: Your doctor should monitor you for increased side effects. They may need to adjust your treatment plan.

Check all your medications →

Common Questions

Can I use roflumilast for sudden breathing problems?
No, roflumilast is not a bronchodilator and will not help with sudden breathing problems.
What should I do if I feel depressed or have suicidal thoughts?
Contact your doctor right away if you experience any changes in mood or have suicidal thoughts.
Will roflumilast cure my COPD?
No, roflumilast does not cure COPD, but it can help reduce the number of flare-ups you experience.
Can I take roflumilast if I have liver problems?
You should not take roflumilast if you have moderate to severe liver problems.
Does roflumilast interact with other medications?
Yes, roflumilast can interact with certain medications. Tell your doctor about all the medicines you take.
Will roflumilast cause weight loss?
Weight loss is a common side effect of roflumilast. Your doctor will monitor your weight.
Can I take roflumilast if I am pregnant or breastfeeding?
It is not recommended to take roflumilast if you are pregnant or breastfeeding.
What is the starting dose of roflumilast?
The starting dose is 250 mcg once daily for the first 4 weeks.
What is the maintenance dose of roflumilast?
The maintenance dose is 500 mcg once daily.
What should I do if I have diarrhea while taking roflumilast?
Diarrhea is a common side effect. Contact your doctor if it is severe or does not go away.
What are the common side effects of roflumilast?
The most commonly reported side effects of roflumilast include Diarrhea, Weight loss, Nausea, Headache, Back pain. Based on 5,435 FDA adverse event reports. Always consult your healthcare provider about potential side effects.
Does roflumilast interact with other medications?
Yes, roflumilast has 8 known drug interactions. Notable interactions include carbamazepine, phenytoin, phenobarbital. Always inform your doctor about all medications you are taking.
What drug class is roflumilast?
roflumilast belongs to the PDE4 Inhibitor drug class. It requires a prescription (Rx). Roflumilast is used to lower your chances of COPD flare-ups.
Is there a generic version of roflumilast?
Yes, generic roflumilast is available from 8 manufacturers. The generic costs $2.34 per unit compared to $14.11 for the brand version, saving approximately 83%. Pricing is based on NADAC (National Average Drug Acquisition Cost) data from CMS.
Is roflumilast safe during pregnancy?
It is not known if roflumilast is safe during pregnancy. Do not breastfeed while taking roflumilast. Always consult your healthcare provider before using any medication during pregnancy or breastfeeding.

Related Medications in PDE4 Inhibitor

Other drugs grouped near roflumilast — same-class peers and common alternatives.

Compare roflumilast vs aclidinium side-by-side →

Medication Guides

Related Health & Safety Data

Save on roflumilast

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for roflumilast

The FDA label for roflumilast (sold under brand names such as Daliresp) classifies it as a prescription-only medication in the PDE4 Inhibitor class. Roflumilast is used to lower your chances of COPD flare-ups. Official labeling lists 9 commonly reported side effects, including Diarrhea, Weight loss, Nausea.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 5,435 voluntary reports. The database also lists 8 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $2.34 versus $14.11 for the brand — a 83% generic savings.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: March 21, 2025

All federal data sources used on this page